摘要
目的 探讨血清中神经特异性烯醇化酶(NSE)水平对晚期非小细胞肺癌(NSCLC)化疗疗效的影响。方法 用放免法检测142例NSCLC治疗前NSE水平,选择阳性病例60例,随机分为两组,A组选用VDS(或NVB)+DDP化疗方案,B组选用Vp-16+DDP化疗方案,评价3周期化疗后的疗效,随访生存率。结果 A组近期化疗有效率为51.2％,1年生存率为16.7％;B组近期化疗有效率为76.7％.1年生存率40.0％,两组差异有显著(P<0.05) 结论 血清NSE水平升高的晚期NACLC患者选用常用的SCLC化疗方案较为合适。
Objective To assess the influence of pretreatment serum neuron-specific enolase (NSE)on chemotherapeutic efficacy in non-small cell lung cancer (NSCLC) .Methods Serum NSE levels were measured in 142 patients with previously untreated NSCLC. Sixty NSE positive cases were divided into two groups(A and B) at random. Cases of group A were treated with VDS(NVB) + DDP chemotherapy, and cases of group B received Vp-16 + DDP chemotherapy. The therapeutic efficacy was evaluated after three cycles of chemotherapy and the survival rate was followeD. Results The response rate was higher in group B (76.7%) than in group A (51.2 % ). The one year survival rate in group A(16.7%) was lower than that in group B(40.0%) .Conclusion The general SCLC chemotherapy regimen is suitable for NSCLC patients with high serum NSE level.
出处
《中国肿瘤临床与康复》
2004年第1期24-26,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
